Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia Academic Article uri icon

Overview

MeSH Major

  • Anemia, Aplastic
  • Cord Blood Stem Cell Transplantation
  • Cyclophosphamide
  • Immunosuppressive Agents
  • Transplantation Conditioning
  • Unrelated Donors

abstract

  • Upfront treatment with risk-adapted cyclophosphamide conditioning AlloSCT is well tolerated for the management of newly diagnosed pediatric and adolescent patients with acquired SAA. However, the increased risk of graft rejection in the lower dose arm warrants additional research regarding the optimal intensity of cyclophosphamide-based conditioning regimen to reduce toxicity without increasing graft failure.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/pbc.24976

PubMed ID

  • 24623601

Additional Document Info

start page

  • 1289

end page

  • 94

volume

  • 61

number

  • 7